Home CONTACT Neoplasma 2014 Neoplasma Vol.61, No.2, p.225-232, 2014

Journal info

6 times a year.
Founded: 1954
ISSN 0028-2685
ISSN 1338-4317 (online)

Published in English

Editorial Info
Abstracted and Indexed
Submission Guidelines

Select Journal

Webshop Cart

Your Cart is currently empty.

Info: Your browser does not accept cookies. To put products into your cart and purchase them you need to enable cookies.

Neoplasma Vol.61, No.2, p.225-232, 2014

Title: Efficacy of a pegaspargase-based regimen in the treatment of newly-diagnosed extranodal natural killer/T-cell lymphoma
Author: L. Li, C. Zhang, L. Zhang, X. Li, J. J. Wu, Z. C. Sun, X. R. Fu, X. H. Wang, Y. Chang, R. Wang, Y. J. Qiu, M. Z. Zhang

Abstract: Extranodal natural killer (NK)/T-cell lymphoma (ENKL) is an aggressive neoplasm with poor prognosis. Currently, there is no consensus on the optimal treatment of this disease. In this study, we report the efficacy of a pegaspargase (PEG-Asp)-based chemotherapy, a DDGP regimen (PEG-Asp, dexamethasone, cisplatin, gemcitabine), for the treatment of newly-diagnosed ENKL. From August 2010 to May 2012, 12 patients with newly-diagnosed stage II – IV ENKL were initially treated with a DDGP regimen in our center. Ten patients (10/12, 83.3%) achieved complete response (CR) and two (2/12, 16.7%) achieved partial response (PR). The objective overall response rate (ORR) was 100%. Three patients (3/12, 25.0%) relapsed, and as a result, two died of disease. Eight patients (8/12, 66.7%) were alive with no evidence of disease (NOD) after a median follow-up of 19 months (range 16 – 31 months). Hematologic toxicity was the most frequent toxicity reported in this study. Grade 3/4 leukopenia and neutropenia were common and both occurred in eight patients (8/12, 66.7%), respectively. Additionally, six patients (6/12, 50.0%) experienced grade 3/4 thrombocytopenia and three (3/12, 25.0%) experienced grade 3/4 anemia. However, no patient died of hematologic toxicity. Our results demonstrate the significant efficacy and safety profile of a DDGP regimen in the treatment of newly-diagnosed ENKL, and indicate the potential of this regimen as a first-line therapy against this disease.

Keywords: pegaspargase, extranodal NK/T-cell lymphoma, non-Hodgkin’s lymphoma, medical oncology
Published online: 02-Dec-2013
Year: 2014, Volume: 61, Issue: 2 Page From: 225, Page To: 232

download file

© AEPress s.r.o
Copyright notice: For any permission to reproduce, archive or otherwise use the documents in the ELiS, please contact AEP.